3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 1
2
Phase 2
1
Phase 1/2
1
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Prostatic Neoplasms
1
Prostate Cancer Metastatic
1
Interventions
pembrolizumab
221
Carboplatin
214
Cisplatin
202
Paclitaxel
181
Gemcitabine
148
Docetaxel
126
Capecitabine
113
Cyclophosphamide
101
Pemetrexed
100
Dexamethasone
100
Specimen Handling
98
Oxaliplatin
96
Magnetic Resonance Spectroscopy
96
Radiotherapy
92
Doxorubicin
91
Fluorouracil
88
Bevacizumab
84
Leucovorin
73
Nivolumab
72
Rituximab
71
Vincristine
67
durvalumab
65
Lenalidomide
64
atezolizumab
61
Radiation
61
Irinotecan
61
Etoposide
60
130-nm albumin-bound paclitaxel
58
Prednisone
55
Letrozole
55
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
fludrocortisone acetate
×
1 year
×
Clear all
NCT06136650
2026-06-03
MK-5684-004
Merck Sharp & Dohme LLC
Phase 3
Recruiting
1,314 enrolled
NCT06136624
2026-05-05
OMAHA-003
Merck Sharp & Dohme LLC
Phase 3
Recruiting
1,310 enrolled